Who Supplies Irbesartan to India from MALTA

Importing finished pharmaceutical formulations containing Irbesartan into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and approved before distribution. The registration process involves obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) and submitting Form 40/41 to CDSCO. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory workload. For formulations under HS Code 30049079, specific requirements include detailed product information, manufacturing licenses, and stability data. It's essential to ensure that the product complies with the Indian Pharmacopoeia standards and that the manufacturing facility holds a valid Good Manufacturing Practice (GMP) certificate.

Imported pharmaceutical formulations containing Irbesartan must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability studies should be conducted under ICH Zone IV conditions to ensure product efficacy and safety in India's climate. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the product. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or additional costs.

In April 2025, the Indian government introduced new regulations mandating import registration and licensing for all imported medicines to prevent the sale of unapproved or illegal drugs. This directive, issued by CDSCO, requires that all imported drugs, including finished formulations containing Irbesartan, obtain prior approval before distribution in India. The implementation of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and potentially reducing reliance on imports. While there are no specific bilateral agreements between India and Malta regarding pharmaceutical imports, adherence to India's regulatory framework is essential for market access.

India imports finished Irbesartan formulations to meet the demand for branded or patented products not manufactured domestically. Specific dosage forms, such as certain tablet strengths or combination therapies, may not be produced locally, necessitating imports. The domestic capacity to produce these formulations is limited, leading to a dependency on imports to fulfill market needs. The market size for Irbesartan formulations in India is substantial, with a growing patient population requiring hypertension management.

The Basic Customs Duty (BCD) for pharmaceutical formulations under HS Code 30049079 is 10%. An additional Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per prevailing rates, which vary based on the product classification and applicable notifications. There are no specific exemptions or concessional duties for products originating from Malta. The total landed duty percentage combines BCD, SWS, and IGST, impacting the final cost of imported goods.

India sources finished Irbesartan formulations from Malta due to the availability of patented or specialized dosage forms not produced domestically. Malta's pharmaceutical industry is known for high-quality manufacturing standards and adherence to international regulatory requirements. While other suppliers, such as China, Germany, and the United States, also export Irbesartan formulations to India, Malta's competitive advantage lies in its compliance with EU GMP standards and the ability to supply specific formulations tailored to market needs. Malta's share in India's Irbesartan import market is relatively small but significant for niche products.

India imports finished Irbesartan formulations from Malta to access patented or specialized dosage forms not available domestically. Malta's pharmaceutical industry offers high-quality products that meet international standards, ensuring efficacy and safety. The ability to supply specific formulations tailored to market needs makes Malta a valuable source for these imports.

When compared to other origins like China, Germany, and the United States, Malta offers competitive advantages in terms of product quality and regulatory compliance. While China may offer lower prices, concerns about quality and regulatory standards can be a drawback. Germany and the United States provide high-quality products but may have higher costs. Malta's unique advantage lies in its balance of quality, compliance, and cost-effectiveness.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but it's prudent to have contingency plans in place. Diversifying suppliers and maintaining adequate inventory levels can mitigate some of these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC) or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with market demand to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure compliance with quality and regulatory standards.

1. 1Obtain a valid Importer Exporter Code (IEC) from DGFT.
2. 2Register the product with CDSCO by submitting Form 40/41.
3. 3Secure a No Objection Certificate (NOC) from DGFT.
4. 4Ensure the manufacturing facility holds a valid GMP certificate.
5. 5Engage a licensed customs broker for import clearance.

6.